MEN Syndromes — MEN1, MEN2A, MEN2B

Multiple Endocrine Neoplasia (MEN) syndromes are hereditary cancer syndromes characterized by tumors in multiple endocrine glands caused by germline mutations in tumor suppressor genes (MEN1) or proto-oncogenes (MEN2A/2B). MEN1 results from inactivating mutations in the MEN1 gene (chromosome 11q13) encoding menin, while MEN2A and MEN2B arise from activating RET proto-oncogene mutations (chromosome 10q11.2). These syndromes have an autosomal dominant inheritance pattern with high penetrance (>95%), presenting in early adulthood with variable expressivity. Understanding MEN syndromes is essential for USMLE Step 2 CK because they represent classic examples of inherited cancer predisposition requiring lifelong surveillance, screening of family members, and preventive intervention. The identification of germline mutations enables genetic counseling and risk stratification that significantly impact patient management and family screening protocols.

The MEN syndromes involve distinct molecular mechanisms that disrupt normal cellular growth control, though all result in neuroendocrine and endocrine neoplasia:

The MEN1 gene encodes menin, a 610-amino acid nuclear protein functioning as a tumor suppressor through multiple pathways. Heterozygous germline MEN1 mutations (frameshift, nonsense, or missense mutations affecting DNA binding) reduce menin expression by 50% in all cells. Tumorigenesis follows the classic Knudson two-hit hypothesis: the inherited first hit (germline mutation) is present in all cells, but tumor formation requires a second somatic MEN1 mutation in target tissues that leads to complete loss of function. Menin normally represses transcription of CDKN1B (p27 kinase inhibitor) and regulates histone methylation; loss of menin dysregulates cell cycle control, impairs MYC-mediated apoptosis, and activates developmental pathways like Wnt and Notch signaling. This explains why MEN1 manifestations are polyendocrine and polyglandular — multiple tissues accumulate second hits affecting the parathyroid (most common, ~95%), anterior pituitary (~40%), and pancreatic islets (~60-70%), with additional NETs in stomach, small bowel, and thyroid.

The RET proto-oncogene (Rearranged During Transfection) encodes a transmembrane receptor tyrosine kinase (RTK) normally expressed in neural crest-derived tissues. Unlike MEN1's loss of function, MEN2A and MEN2B arise from germline activating mutations in RET that cause constitutive (ligand-independent) kinase activity. These mutations cluster in specific domains: MEN2A mutations typically occur in extracellular cysteine-rich regions (codons 609, 611, 618, 620) and intracellular tyrosine kinase domain (codon 634), while MEN2B features a specific codon 918 methionine→threonine (M918T) mutation in the kinase domain that dramatically increases catalytic activity and alters substrate specificity. Constitutive RET signaling drives uncontrolled proliferation through hyperactivation of MAPK (Ras/RAF/MEK/ERK), PI3K/Akt, and PLCγ pathways, leading to medullary thyroid carcinoma (MTC) in nearly 100% of MEN2 carriers by age 70 (MEN2A) or childhood (MEN2B). The specific codon location predicts phenotypic severity: codon 634 mutations carry highest MTC risk and earlier onset; MEN2B's M918T mutation causes earlier, more aggressive MTC and distinctive mucosal neuromas and marfanoid habitus, suggesting RET hyperactivity's developmental consequences extend beyond neuroendocrine tissues.

Although germline mutations are present in all cells, MEN manifestations demonstrate striking tissue selectivity based on developmental origin and RET/menin expression patterns. In MEN1, target tissues (parathyroid, gastroenteropancreatic NETs, pituitary) share developmental origin from foregut endoderm or neural crest and have high proliferative potential. Parathyroid demonstrates unique monoclonal or oligoclonal expansion of tumors, suggesting preferential second hits in this tissue. In MEN2, RET expression is high in C-cells (embryologically from neural crest) derived from ultimobranchial body, explaining universal MTC penetrance, whereas pheochromocytomas occur in ~50% MEN2A and <5% MEN2B, likely due to differences in RET signaling intensity and tissue microenvironment effects on adrenomedullary progenitors. Temporal sequencing is critical: in MEN2A/2B, MTC is the earliest neoplasm (often present by age 10-20), whereas hyperparathyroidism typically develops later, reflecting different rates of clonal evolution and selective pressures in each tissue.

In MEN1-associated primary hyperparathyroidism, menin loss dysregulates PTH secretion through multiple mechanisms: impaired CDKN1B-mediated inhibition of cyclin-CDK complexes allows uncontrolled parathyroid cell proliferation; loss of menin-mediated repression of developmental genes permits cells to maintain immature, proliferative phenotypes; and possible defects in calcium-sensing mechanisms reduce suppression of PTH secretion at normal serum calcium levels. Histologically, parathyroid shows multiglandular hyperplasia (all 4 glands involved) requiring subtotal parathyroidectomy rather than adenoma resection. In MEN2A-associated hyperparathyroidism, RET activation's role is less direct — hyperparathyroidism is less frequent (~20-30%) and develops later in life; the mechanism likely involves somatic CASR or other mutations in parathyroid tissue during aging, rather than direct RET signaling in parathyroid cells (which express RET minimally). This distinction explains why MEN1 hyperparathyroidism is often symptomatic and severe, while MEN2A hyperparathyroidism may be asymptomatic and discovered incidentally on screening.

Pathogenic MEN1 mutations occur in ~3% of the general population (estimated prevalence 1:20,000–1:30,000) and are inherited in autosomal dominant fashion with 100% penetrance by age 40. Over 1,200 distinct MEN1 mutations have been identified, distributed throughout the gene: frameshift mutations (40%), nonsense mutations (25%), missense mutations (20%), and splice-site mutations (15%) are all represented. Approximately 10% of cases represent de novo mutations (spontaneous, not inherited from affected parent), important for counseling newly diagnosed patients. Family history is absent in these de novo cases, but 90% have an identifiable affected parent with incomplete penetrance or variable expressivity masking the diagnosis. Genetic testing involves **sequencing the entire MEN1 coding region and introns** to identify pathogenic variants; clinical genetic testing is recommended for all patients with features of MEN1 or first-degree relatives of affected individuals, with detection rates >90% in clinically symptomatic patients.

MEN2A results from activating RET germline mutations, most commonly in cysteine-rich extracellular domains (codons 609, 611, 618, 620) or the intracellular tyrosine kinase domain (codon 634). Cysteine substitutions promote RET dimerization and ligand-independent activation, while codon 634 mutations (typically cysteine→arginine or serine) dramatically increase kinase activity and alter substrate specificity. MEN2A prevalence is estimated at 1:30,000–1:50,000 and accounts for ~80% of RET-positive MEN2 cases. Codon 634 mutations carry the highest penetrance for MTC (approaching 100% by age 50) and pheochromocytoma risk (~50%), while extracellular cysteine mutations have slightly lower MTC penetrance (~95%) and pheochromocytoma prevalence (~5-10%). Genetic testing involves RET exon sequencing, focusing initially on common mutation hotspots (codons 634, 609-620) with >95% sensitivity.

MEN2B is caused by a **specific RET codon 918 M918T mutation found in ~95% of MEN2B patients, making it the most homogeneous of the MEN syndromes genetically. This mutation is nearly always inherited de novo (~50% of cases) or inherited paternally (~40% due to paternal age effect, suggesting increased mutagenesis in male meiosis), with maternal inheritance less common (~10%), possibly reflecting selective pressure against maternal transmission. The codon 918 mutation occurs in a critical adenosine triphosphate (ATP)-binding pocket of the RTK domain, creating a methionine→threonine substitution that increases RET catalytic activity ~30-fold and alters substrate specificity to activate unique signaling pathways. MEN2B prevalence is 1:100,000 or less. This genetic homogeneity contrasts sharply with MEN1's genetic heterogeneity and makes RET exon 16 (containing codon 918) sequencing** the critical first test in suspected MEN2B; codon 918 testing alone has ~95% sensitivity but should be followed by full RET sequencing to exclude other activating mutations.

Presents with primary hyperparathyroidism as the earliest recognizable feature, often appearing in the second-third decade of life. Clinical manifestations follow from hypercalcemia: nephrolithiasis (calcium phosphate or calcium oxalate stones in 60-70%), nephrogenic diabetes insipidus (polyuria, polydipsia), osteoporosis/osteopenia with bone loss accelerated by PTH excess and hypercalcemia, and neuropsychiatric symptoms (depression, cognitive slowing, memory impairment) caused by hypercalcemia's effects on neuronal excitability and mood regulation. Hyperparathyroidism in MEN1 is notably multiglandular rather than single adenoma; patients typically have markedly elevated PTH levels (often 2-3× upper normal) with serum calcium 11-13 mg/dL at presentation (vs. mild elevation in sporadic adenomas). A characteristic finding is hypercalciuria despite elevated PTH, reflecting PTH resistance in kidney or renal loss overriding PTH's calcium-reabsorbing effects. Biochemically, hyperparathyroidism is discovered on routine screening or when investigating hypercalcemia; simultaneous elevated ionized calcium with PTH >15 pg/mL confirms primary hyperparathyroidism.

Gastrinomas are the most common functional GEP-NET in MEN1 (occurring in ~20-40% of patients), causing Zollinger-Ellison syndrome (ZES) with severe gastroesophageal reflux disease (GERD), chronic diarrhea, and peptic ulcer disease often refractory to standard antisecretory therapy. ZES presents with fasting serum gastrin >10× upper limit of normal (>1000 pg/mL typical) and gastric pH <2. These gastrinomas are typically duodenal (70%) rather than pancreatic, multifocal, and frequently malignant with liver metastases at presentation (~70%). Insulinomas occur in ~10% of MEN1 patients, causing hypoglycemia (plasma glucose <55 mg/dL) with inappropriate insulin secretion (insulin >3 μU/mL, C-peptide >0.6 ng/mL during hypoglycemia), presenting with neuroglycopenic symptoms (confusion, seizures, loss of consciousness) and adrenergic symptoms (palpitations, tremor, diaphoresis). Non-functional pancreatic NETs are increasingly recognized in ~40% of MEN1 patients through surveillance imaging and typically present with pancreatic masses without hormonal hypersecretion syndromes; their clinical significance relates to malignant potential and metastatic risk, not hormone excess. Carcinoid tumors arise in foregut tissues in MEN1: gastric carcinoids (type 3, associated with Zollinger-Ellison or chronic atrophic gastritis) and thymic/bronchial carcinoids (occur in ~2-8%, presenting with cough, chest pain, or incidental finding on imaging) represent important neuroendocrine malignancies requiring surveillance.

Prolactinomas are the most common pituitary manifestation in MEN1 (occurring in 20-30% of patients), presenting with hypogonadism (amenorrhea/infertility in women, erectile dysfunction/low libido in men), galactorrhea, and headaches/visual field defects if macroadenoma. Prolactin is typically markedly elevated (>200 ng/mL in macroadenomas). Growth hormone-secreting adenomas (acromegaly) occur in ~10% of MEN1, presenting with progressive coarsening of facial features, enlarged hands/feet, macroglossia, prognathism, sleep apnea, hypertension, diabetes, with fasting GH >1 ng/mL and IGF-1 elevated for age. Non-functional adenomas are discovered incidentally on pituitary imaging in ~5-10% and may present with mass effects (headache, visual field defect) or hypopituitarism from compression. Pituitary carcinomas are rare but documented in MEN1.

Adrenocortical tumors (benign adenomas) occur in 40% but are rarely hormonally active (<5% cause Cushing syndrome or primary aldosteronism). Cutaneous lesions are highly characteristic: lipomas (present in 80%, multiple, subcutaneous), collagenomas (skin nodules from collagen deposition, ~70%), and café-au-lait spots (hyperpigmented macules, ~25-30%), though these lack diagnostic specificity. Thyroid adenomas (benign, ~25%) occur but rarely cause thyroid dysfunction. Carcinoid tumors in atypical locations (jejunal, ileal, colonic NETs) add to cancer risk.

MTC arises from parafollicular C-cells and is the most penetrant and earliest manifestation of MEN2A, often presenting in